company background image
CVM

CEL-SCI NYSEAM:CVM Stock Report

Last Price

US$3.30

Market Cap

US$143.1m

7D

-2.4%

1Y

-69.8%

Updated

03 Oct, 2022

Data

Company Financials +
CVM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CVM Stock Overview

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases.

CEL-SCI Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CEL-SCI
Historical stock prices
Current Share PriceUS$3.30
52 Week HighUS$12.82
52 Week LowUS$2.49
Beta1.69
1 Month Change-14.06%
3 Month Change-20.86%
1 Year Change-69.78%
3 Year Change-64.21%
5 Year Change95.27%
Change since IPO-99.96%

Recent News & Updates

Shareholder Returns

CVMUS BiotechsUS Market
7D-2.4%3.9%1.0%
1Y-69.8%-22.7%-20.0%

Return vs Industry: CVM underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: CVM underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is CVM's price volatile compared to industry and market?
CVM volatility
CVM Average Weekly Movement13.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CVM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: CVM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1983n/aGeert Kerstenhttps://cel-sci.com

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company’s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

CEL-SCI Corporation Fundamentals Summary

How do CEL-SCI's earnings and revenue compare to its market cap?
CVM fundamental statistics
Market CapUS$143.11m
Earnings (TTM)-US$36.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CVM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$24.18m
Gross Profit-US$24.18m
Other ExpensesUS$12.55m
Earnings-US$36.74m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CVM perform over the long term?

See historical performance and comparison